GlassScriptPhysician profile
Kyle Monroe Knabb
NPI 1922372788
$2,301.60
in general payments reported to CMS, 2019-2025
28 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $302 · 2021: $386 · 2022: $231 · 2023: $212 · 2024: $93.76 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $317.56 | 2019-2022 | |
| Abbvie INC. | $219.32 | 2021-2025 | |
| Novo Nordisk INC | $203.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $178.20 | 2020-2024 | Farxiga |
| Acelrx Pharmaceuticals, INC. | $169.69 | 2019-2020 | |
| Allergan, INC. | $161.71 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $120.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $107.97 | 2020-2025 | |
| Medtronic Vascular, INC. | $95.12 | 2019 | |
| Abiomed | $77.15 | 2023 | Impella |
| Pfizer INC. | $56.55 | 2020-2025 | |
| Corcept Therapeutics | $52.98 | 2024-2025 | Korlym |
| Abbott Laboratories | $47.28 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $46.16 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43.37 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $41.06 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $35.31 | 2019 | |
| Eisai INC. | $34.50 | 2021 | |
| Melinta Therapeutics, LLC | $28.01 | 2019 | |
| Heartflow, INC. | $22.43 | 2023 | Ffrct |
| Amarin Pharma, INC. | $22.32 | 2020 | |
| Edwards Lifesciences Corporation | $19.13 | 2019 | |
| Medtronic, INC. | $17.50 | 2025 | Closurefast |
| Astellas Pharma US INC | $16.00 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $15.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.91 | 2019 | |
| Glaxosmithkline, LLC. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Knabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.